United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Monday, October 26th. The shares were sold at an average price of $588.64, for a total transaction of $5,592,080.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at $190,980,127.52. The trade was a 2.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

United Therapeutics Price Performance

UTHR stock opened at $591.20 on Wednesday. The company’s 50-day simple moving average is $522.90 and its 200-day simple moving average is $528.93. United Therapeutics Corporation has a 52-week low of $409.07 and a 52-week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same quarter last year, the business earned $6.41 earnings per share. United Therapeutics’s revenue was down 1.9% on a year-over-year basis. On average, sell-side analysts forecast that United Therapeutics Corporation will post 26.07 EPS for the current year.

United Therapeutics declared that its Board of Directors has initiated a share repurchase program on Thursday, October 22nd that allows the company to buy back $2 billion in outstanding shares. This buyback authorization allows the biotechnology company to purchase up to 8.3% of its shares through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its shares are undervalued.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of UTHR. BOKF NA grew its position in shares of United Therapeutics by 12.3% in the third quarter. BOKF NA now owns 7,834 shares of the biotechnology company’s stock valued at $4,245,000 after purchasing an additional 857 shares in the last quarter. Asset Management One Co. Ltd. grew its holdings in United Therapeutics by 1.9% in the 3rd quarter. Asset Management One Co. Ltd. now owns 23,166 shares of the biotechnology company’s stock valued at $12,553,000 after buying an additional 424 shares in the last quarter. Kingswood Wealth Advisors LLC grew its holdings in United Therapeutics by 8.7% in the 3rd quarter. Kingswood Wealth Advisors LLC now owns 628 shares of the biotechnology company’s stock valued at $340,000 after buying an additional 50 shares in the last quarter. Citizens Financial Group Inc. RI grew its holdings in United Therapeutics by 26.5% in the 3rd quarter. Citizens Financial Group Inc. RI now owns 912 shares of the biotechnology company’s stock valued at $494,000 after buying an additional 191 shares in the last quarter. Finally, One Wealth Capital Management LLC acquired a new stake in shares of United Therapeutics in the 3rd quarter worth $323,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have commented on UTHR. Leerink Partners raised their price objective on United Therapeutics from $685.00 to $725.00 and gave the company an “outperform” rating in a report on Monday, October 19th. Morgan Stanley increased their target price on United Therapeutics from $515.00 to $566.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 7th. Cantor Fitzgerald reissued an “overweight” rating and issued a $850.00 price target on shares of United Therapeutics in a research note on Monday. JPMorgan Chase & Co. boosted their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Finally, UBS Group set a $725.00 price target on shares of United Therapeutics in a report on Monday, October 19th. Twelve equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $666.50.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.